Scancell’s Modi-1 Vaccine Shows Promising Early Results in Cancer Treatment

Scancell Holdings ( (GB:SCLP) ) just unveiled an update.

Scancell Holdings has achieved early clinical validation for its Modi-1 Moditope® vaccine in treating HPV-negative head and neck squamous cell carcinoma, showing a partial response in 43% of patients compared to lower historical rates with standard treatments. This success, along with new patent approval in the US, enhances the commercial positioning of Modi-1 Moditope®, potentially improving the company’s competitiveness in the cancer vaccine market.

More about Scancell Holdings

Scancell Holdings is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. The company utilizes its proprietary research in the human adaptive immune system to create innovative medicines, leveraging technology platforms such as Moditope® and ImmunoBody® for vaccines, and GlyMab® and AvidiMab® for antibodies. These platforms aim to treat significant unmet needs in cancer by inducing immune responses and redirecting immune cells or drugs to target protein and lipid modifications.

YTD Price Performance: -6.05%

Average Trading Volume: 949,111

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: £104.7M

See more insights into SCLP stock on TipRanks’ Stock Analysis page.